Review Article

Research Progress of Population Pharmacokinetic of Metformin

Table 1

Demographics of the published population pharmacokinetic studies.

StudySiteMale/femaleAge (year)Weight (kg)Dose regimen (mg/day)AssaySubject characteristicsType of study

2006 Charles [28]Australia0/2732 (26–43)88 (50–150)2000 (1000–3000) mgHPLCT2DM with late pregnancyProspective
2008 Hong [25]America3/956 (45-63)89(70-127)500 mg,5d, bid;
850,5d, bid
LC/MS/MST2DMProspective
2012 Jung-woo [18]Korea42/026(21-31)69(61-78)Single oral 500 mgLC-MS/MSHealthyProspective
2013 Yoon [22]South Korea96/022.41(19-31)67.74(53.1-95.6)Single oral 500 mgHPLC-UVHealthyRetrospective
2013 Duong [19]AustraliaNAA: 65 (39–86)
B: 27 (19–40)
C: 23 (18–47)
A: 86 (53–165)
B: 70 (53–103)
C: 58 (41–88)
A: 1,500 (250–3,000)
B: 1,000 (500–2,000)
C: 500 (500–1,000)
HPLC-UVHealthy; T2DM
A: T2DM, CKD
B: Healthy
C: Healthy
Retrospective
2014 Goswami [20]AmericaNA46 (18-90)86.4 (34-212)Healthy:1850/850 mg
T2DM: NA
NAHealthy:T2DM
102 : 133
Prospective
2016 Chitnis [26]America159/17725.0 (18–50)64.7 (45.0–111.1)NALC-MSHealthyRetrospective
2016 Sam [23]AmericaNA11.2 (7.7-13.5)77 (50.5-118)1000 mg, bidUPLCSeverely obese children with insulin resistance.Prospective
2018 Choi [21]South Korea36/023.9(20.0-42.0)176(169.1-183.5)NALC/MS/MSHealthyProspective
2020 Sinnappah [27]Australia3/270(61-82)86(78-102)500 mg, three times a weekUPLC-MS/MST2DM patients undergoing hemodialysisProspective
2020 Ling [24]China85/4056 (27–83)75 (51–113)2000 (1000–2000) mgHPLC-UVT2DMProspective

NA: Represents the missing value, which is not mentioned in the article; T2DM: Type2 diabetes mellitus; HPLC: High-performance liquid chromatography; CKD: Chronic kidney disease.